tiprankstipranks
Advertisement
Advertisement

BLCO Stock Latest News

Bausch + Lomb announces narrative review on certain B vitamins
The FlyBausch + Lomb announces narrative review on certain B vitamins
4d ago
BLCO
Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled
PremiumThe Fly
Bausch + Lomb reports nearly 725k lbs. of eye care materials recycled
11d ago
BLCO
Bausch + Lomb Wins FDA Clearance for Next-Generation Vitrectomy Cutter and Fluidics Upgrade
PremiumCompany Announcements
Bausch + Lomb Wins FDA Clearance for Next-Generation Vitrectomy Cutter and Fluidics Upgrade
19d ago
BLCO
Bausch + Lomb receives FDA 510k clearance for Bi-Blade+
PremiumThe Fly
Bausch + Lomb receives FDA 510k clearance for Bi-Blade+
19d ago
BLCO
Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe
PremiumCompany Announcements
Bausch + Lomb Rolls Out enVista Envy Premium Intraocular Lens Across Europe
20d ago
BLCO
Bausch + Lomb announces European availability of enVista Envy lenses
PremiumThe FlyBausch + Lomb announces European availability of enVista Envy lenses
20d ago
BLCO
Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting
Premium
Company Announcements
Bausch + Lomb to Unveil Broad New Ophthalmic Data at ASCRS Meeting
21d ago
BLCO
Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI
Premium
The Fly
Bausch + Lomb price target lowered to $17 from $17.50 at Evercore ISI
21d ago
BLCO
Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call
PremiumCompany Announcements
Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call
28d ago
BLCO
Bausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial
PremiumCompany Announcements
Bausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial
1M ago
BLCO
Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma
PremiumThe Fly
Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma
1M ago
BLCO
Bausch + Lomb Launches R&D Webinar Series Spotlighting Glaucoma Pipeline
PremiumCompany Announcements
Bausch + Lomb Launches R&D Webinar Series Spotlighting Glaucoma Pipeline
2M ago
BLCO
Trump Trade: L’Oreal, Bausch + Lomb sue for Trump tariff refunds
PremiumThe FlyTrump Trade: L’Oreal, Bausch + Lomb sue for Trump tariff refunds
2M ago
C
GS
L’Oreal, Bausch + Lomb sue for Trump tariff refunds, Reuters reports
Premium
The Fly
L’Oreal, Bausch + Lomb sue for Trump tariff refunds, Reuters reports
2M ago
GT
FDX
Bausch + Lomb Leverages New Global Review to Spotlight LUMIFY’s Edge in Rising Ocular Redness Market
Premium
Company Announcements
Bausch + Lomb Leverages New Global Review to Spotlight LUMIFY’s Edge in Rising Ocular Redness Market
2M ago
BLCO
Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright
PremiumThe Fly
Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright
2M ago
BLCO
Bausch + Lomb price target raised to $15 from $13 at BofA
PremiumThe Fly
Bausch + Lomb price target raised to $15 from $13 at BofA
2M ago
BHC
BLCO
Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank
PremiumThe Fly
Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank
2M ago
BLCO
Bausch + Lomb price target raised to $16 from $15 at Stifel
PremiumThe Fly
Bausch + Lomb price target raised to $16 from $15 at Stifel
2M ago
BLCO
Bausch + Lomb price target raised to $21 from $20 at Citi
PremiumThe FlyBausch + Lomb price target raised to $21 from $20 at Citi
2M ago
BLCO
Bausch + Lomb price target raised to $20 from $17 at Barclays
Premium
The Fly
Bausch + Lomb price target raised to $20 from $17 at Barclays
2M ago
BLCO
Maintaining Sell: Structural Overhangs and Margin Shortfalls Overshadow Bausch + Lomb’s Growth Story
Premium
Ratings
Maintaining Sell: Structural Overhangs and Margin Shortfalls Overshadow Bausch + Lomb’s Growth Story
2M ago
BLCO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >